Global PD-1 and PD-L1 Monoclonal Antibody Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “PD-1 and PD-L1 Monoclonal Antibody Industry Forecast” looks at past sales and reviews total world PD-1 and PD-L1 Monoclonal Antibody sales in 2022, providing a comprehensive analysis by region and market sector of projected PD-1 and PD-L1 Monoclonal Antibody sales for 2023 through 2029. With PD-1 and PD-L1 Monoclonal Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-1 and PD-L1 Monoclonal Antibody industry.
This Insight Report provides a comprehensive analysis of the global PD-1 and PD-L1 Monoclonal Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PD-1 and PD-L1 Monoclonal Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global PD-1 and PD-L1 Monoclonal Antibody market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-1 and PD-L1 Monoclonal Antibody and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-1 and PD-L1 Monoclonal Antibody.
The global PD-1 and PD-L1 Monoclonal Antibody market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for PD-1 and PD-L1 Monoclonal Antibody is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for PD-1 and PD-L1 Monoclonal Antibody is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for PD-1 and PD-L1 Monoclonal Antibody is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key PD-1 and PD-L1 Monoclonal Antibody players cover Merk, Bristol-Myers Squibb Company, Roche, Pfizer, AstraZeneca, Junshi Biosciences, Innovent, Hengrui and BeiGene, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of PD-1 and PD-L1 Monoclonal Antibody market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global PD-1 and PD-L1 Monoclonal Antibody market?
What factors are driving PD-1 and PD-L1 Monoclonal Antibody market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PD-1 and PD-L1 Monoclonal Antibody market opportunities vary by end market size?
How does PD-1 and PD-L1 Monoclonal Antibody break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “PD-1 and PD-L1 Monoclonal Antibody Industry Forecast” looks at past sales and reviews total world PD-1 and PD-L1 Monoclonal Antibody sales in 2022, providing a comprehensive analysis by region and market sector of projected PD-1 and PD-L1 Monoclonal Antibody sales for 2023 through 2029. With PD-1 and PD-L1 Monoclonal Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-1 and PD-L1 Monoclonal Antibody industry.
This Insight Report provides a comprehensive analysis of the global PD-1 and PD-L1 Monoclonal Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PD-1 and PD-L1 Monoclonal Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global PD-1 and PD-L1 Monoclonal Antibody market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-1 and PD-L1 Monoclonal Antibody and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-1 and PD-L1 Monoclonal Antibody.
The global PD-1 and PD-L1 Monoclonal Antibody market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for PD-1 and PD-L1 Monoclonal Antibody is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for PD-1 and PD-L1 Monoclonal Antibody is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for PD-1 and PD-L1 Monoclonal Antibody is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key PD-1 and PD-L1 Monoclonal Antibody players cover Merk, Bristol-Myers Squibb Company, Roche, Pfizer, AstraZeneca, Junshi Biosciences, Innovent, Hengrui and BeiGene, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of PD-1 and PD-L1 Monoclonal Antibody market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- PD-1
- PD-L1
- Lung Cancer
- Liver Cancer
- Esophageal Cancer
- Gastric Cancer
- Nasopharyngeal Carcinoma
- Head and Neck Cancer
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merk
- Bristol-Myers Squibb Company
- Roche
- Pfizer
- AstraZeneca
- Junshi Biosciences
- Innovent
- Hengrui
- BeiGene
- Alphamab Oncology
- Cstone
- Akeso
What is the 10-year outlook for the global PD-1 and PD-L1 Monoclonal Antibody market?
What factors are driving PD-1 and PD-L1 Monoclonal Antibody market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PD-1 and PD-L1 Monoclonal Antibody market opportunities vary by end market size?
How does PD-1 and PD-L1 Monoclonal Antibody break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PD-1 and PD-L1 Monoclonal Antibody Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for PD-1 and PD-L1 Monoclonal Antibody by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for PD-1 and PD-L1 Monoclonal Antibody by Country/Region, 2018, 2022 & 2029
2.2 PD-1 and PD-L1 Monoclonal Antibody Segment by Type
2.2.1 PD-1
2.2.2 PD-L1
2.3 PD-1 and PD-L1 Monoclonal Antibody Sales by Type
2.3.1 Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2018-2023)
2.3.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue and Market Share by Type (2018-2023)
2.3.3 Global PD-1 and PD-L1 Monoclonal Antibody Sale Price by Type (2018-2023)
2.4 PD-1 and PD-L1 Monoclonal Antibody Segment by Application
2.4.1 Lung Cancer
2.4.2 Liver Cancer
2.4.3 Esophageal Cancer
2.4.4 Gastric Cancer
2.4.5 Nasopharyngeal Carcinoma
2.4.6 Head and Neck Cancer
2.4.7 Other
2.5 PD-1 and PD-L1 Monoclonal Antibody Sales by Application
2.5.1 Global PD-1 and PD-L1 Monoclonal Antibody Sale Market Share by Application (2018-2023)
2.5.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue and Market Share by Application (2018-2023)
2.5.3 Global PD-1 and PD-L1 Monoclonal Antibody Sale Price by Application (2018-2023)
3 GLOBAL PD-1 AND PD-L1 MONOCLONAL ANTIBODY BY COMPANY
3.1 Global PD-1 and PD-L1 Monoclonal Antibody Breakdown Data by Company
3.1.1 Global PD-1 and PD-L1 Monoclonal Antibody Annual Sales by Company (2018-2023)
3.1.2 Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Company (2018-2023)
3.2 Global PD-1 and PD-L1 Monoclonal Antibody Annual Revenue by Company (2018-2023)
3.2.1 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Company (2018-2023)
3.2.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Company (2018-2023)
3.3 Global PD-1 and PD-L1 Monoclonal Antibody Sale Price by Company
3.4 Key Manufacturers PD-1 and PD-L1 Monoclonal Antibody Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PD-1 and PD-L1 Monoclonal Antibody Product Location Distribution
3.4.2 Players PD-1 and PD-L1 Monoclonal Antibody Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR PD-1 AND PD-L1 MONOCLONAL ANTIBODY BY GEOGRAPHIC REGION
4.1 World Historic PD-1 and PD-L1 Monoclonal Antibody Market Size by Geographic Region (2018-2023)
4.1.1 Global PD-1 and PD-L1 Monoclonal Antibody Annual Sales by Geographic Region (2018-2023)
4.1.2 Global PD-1 and PD-L1 Monoclonal Antibody Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic PD-1 and PD-L1 Monoclonal Antibody Market Size by Country/Region (2018-2023)
4.2.1 Global PD-1 and PD-L1 Monoclonal Antibody Annual Sales by Country/Region (2018-2023)
4.2.2 Global PD-1 and PD-L1 Monoclonal Antibody Annual Revenue by Country/Region (2018-2023)
4.3 Americas PD-1 and PD-L1 Monoclonal Antibody Sales Growth
4.4 APAC PD-1 and PD-L1 Monoclonal Antibody Sales Growth
4.5 Europe PD-1 and PD-L1 Monoclonal Antibody Sales Growth
4.6 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales Growth
5 AMERICAS
5.1 Americas PD-1 and PD-L1 Monoclonal Antibody Sales by Country
5.1.1 Americas PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023)
5.1.2 Americas PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023)
5.2 Americas PD-1 and PD-L1 Monoclonal Antibody Sales by Type
5.3 Americas PD-1 and PD-L1 Monoclonal Antibody Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-1 and PD-L1 Monoclonal Antibody Sales by Region
6.1.1 APAC PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2018-2023)
6.1.2 APAC PD-1 and PD-L1 Monoclonal Antibody Revenue by Region (2018-2023)
6.2 APAC PD-1 and PD-L1 Monoclonal Antibody Sales by Type
6.3 APAC PD-1 and PD-L1 Monoclonal Antibody Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe PD-1 and PD-L1 Monoclonal Antibody by Country
7.1.1 Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023)
7.1.2 Europe PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023)
7.2 Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Type
7.3 Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody by Country
8.1.1 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023)
8.1.2 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023)
8.2 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Type
8.3 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PD-1 and PD-L1 Monoclonal Antibody
10.3 Manufacturing Process Analysis of PD-1 and PD-L1 Monoclonal Antibody
10.4 Industry Chain Structure of PD-1 and PD-L1 Monoclonal Antibody
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PD-1 and PD-L1 Monoclonal Antibody Distributors
11.3 PD-1 and PD-L1 Monoclonal Antibody Customer
12 WORLD FORECAST REVIEW FOR PD-1 AND PD-L1 MONOCLONAL ANTIBODY BY GEOGRAPHIC REGION
12.1 Global PD-1 and PD-L1 Monoclonal Antibody Market Size Forecast by Region
12.1.1 Global PD-1 and PD-L1 Monoclonal Antibody Forecast by Region (2024-2029)
12.1.2 Global PD-1 and PD-L1 Monoclonal Antibody Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global PD-1 and PD-L1 Monoclonal Antibody Forecast by Type
12.7 Global PD-1 and PD-L1 Monoclonal Antibody Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Merk
13.1.1 Merk Company Information
13.1.2 Merk PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.1.3 Merk PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Merk Main Business Overview
13.1.5 Merk Latest Developments
13.2 Bristol-Myers Squibb Company
13.2.1 Bristol-Myers Squibb Company Company Information
13.2.2 Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.2.3 Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Bristol-Myers Squibb Company Main Business Overview
13.2.5 Bristol-Myers Squibb Company Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.3.3 Roche PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.4.3 Pfizer PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 AstraZeneca
13.5.1 AstraZeneca Company Information
13.5.2 AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.5.3 AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 AstraZeneca Main Business Overview
13.5.5 AstraZeneca Latest Developments
13.6 Junshi Biosciences
13.6.1 Junshi Biosciences Company Information
13.6.2 Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.6.3 Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Junshi Biosciences Main Business Overview
13.6.5 Junshi Biosciences Latest Developments
13.7 Innovent
13.7.1 Innovent Company Information
13.7.2 Innovent PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.7.3 Innovent PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Innovent Main Business Overview
13.7.5 Innovent Latest Developments
13.8 Hengrui
13.8.1 Hengrui Company Information
13.8.2 Hengrui PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.8.3 Hengrui PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Hengrui Main Business Overview
13.8.5 Hengrui Latest Developments
13.9 BeiGene
13.9.1 BeiGene Company Information
13.9.2 BeiGene PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.9.3 BeiGene PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 BeiGene Main Business Overview
13.9.5 BeiGene Latest Developments
13.10 Alphamab Oncology
13.10.1 Alphamab Oncology Company Information
13.10.2 Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.10.3 Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Alphamab Oncology Main Business Overview
13.10.5 Alphamab Oncology Latest Developments
13.11 Cstone
13.11.1 Cstone Company Information
13.11.2 Cstone PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.11.3 Cstone PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Cstone Main Business Overview
13.11.5 Cstone Latest Developments
13.12 Akeso
13.12.1 Akeso Company Information
13.12.2 Akeso PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.12.3 Akeso PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Akeso Main Business Overview
13.12.5 Akeso Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PD-1 and PD-L1 Monoclonal Antibody Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for PD-1 and PD-L1 Monoclonal Antibody by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for PD-1 and PD-L1 Monoclonal Antibody by Country/Region, 2018, 2022 & 2029
2.2 PD-1 and PD-L1 Monoclonal Antibody Segment by Type
2.2.1 PD-1
2.2.2 PD-L1
2.3 PD-1 and PD-L1 Monoclonal Antibody Sales by Type
2.3.1 Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2018-2023)
2.3.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue and Market Share by Type (2018-2023)
2.3.3 Global PD-1 and PD-L1 Monoclonal Antibody Sale Price by Type (2018-2023)
2.4 PD-1 and PD-L1 Monoclonal Antibody Segment by Application
2.4.1 Lung Cancer
2.4.2 Liver Cancer
2.4.3 Esophageal Cancer
2.4.4 Gastric Cancer
2.4.5 Nasopharyngeal Carcinoma
2.4.6 Head and Neck Cancer
2.4.7 Other
2.5 PD-1 and PD-L1 Monoclonal Antibody Sales by Application
2.5.1 Global PD-1 and PD-L1 Monoclonal Antibody Sale Market Share by Application (2018-2023)
2.5.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue and Market Share by Application (2018-2023)
2.5.3 Global PD-1 and PD-L1 Monoclonal Antibody Sale Price by Application (2018-2023)
3 GLOBAL PD-1 AND PD-L1 MONOCLONAL ANTIBODY BY COMPANY
3.1 Global PD-1 and PD-L1 Monoclonal Antibody Breakdown Data by Company
3.1.1 Global PD-1 and PD-L1 Monoclonal Antibody Annual Sales by Company (2018-2023)
3.1.2 Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Company (2018-2023)
3.2 Global PD-1 and PD-L1 Monoclonal Antibody Annual Revenue by Company (2018-2023)
3.2.1 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Company (2018-2023)
3.2.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Company (2018-2023)
3.3 Global PD-1 and PD-L1 Monoclonal Antibody Sale Price by Company
3.4 Key Manufacturers PD-1 and PD-L1 Monoclonal Antibody Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PD-1 and PD-L1 Monoclonal Antibody Product Location Distribution
3.4.2 Players PD-1 and PD-L1 Monoclonal Antibody Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR PD-1 AND PD-L1 MONOCLONAL ANTIBODY BY GEOGRAPHIC REGION
4.1 World Historic PD-1 and PD-L1 Monoclonal Antibody Market Size by Geographic Region (2018-2023)
4.1.1 Global PD-1 and PD-L1 Monoclonal Antibody Annual Sales by Geographic Region (2018-2023)
4.1.2 Global PD-1 and PD-L1 Monoclonal Antibody Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic PD-1 and PD-L1 Monoclonal Antibody Market Size by Country/Region (2018-2023)
4.2.1 Global PD-1 and PD-L1 Monoclonal Antibody Annual Sales by Country/Region (2018-2023)
4.2.2 Global PD-1 and PD-L1 Monoclonal Antibody Annual Revenue by Country/Region (2018-2023)
4.3 Americas PD-1 and PD-L1 Monoclonal Antibody Sales Growth
4.4 APAC PD-1 and PD-L1 Monoclonal Antibody Sales Growth
4.5 Europe PD-1 and PD-L1 Monoclonal Antibody Sales Growth
4.6 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales Growth
5 AMERICAS
5.1 Americas PD-1 and PD-L1 Monoclonal Antibody Sales by Country
5.1.1 Americas PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023)
5.1.2 Americas PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023)
5.2 Americas PD-1 and PD-L1 Monoclonal Antibody Sales by Type
5.3 Americas PD-1 and PD-L1 Monoclonal Antibody Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-1 and PD-L1 Monoclonal Antibody Sales by Region
6.1.1 APAC PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2018-2023)
6.1.2 APAC PD-1 and PD-L1 Monoclonal Antibody Revenue by Region (2018-2023)
6.2 APAC PD-1 and PD-L1 Monoclonal Antibody Sales by Type
6.3 APAC PD-1 and PD-L1 Monoclonal Antibody Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe PD-1 and PD-L1 Monoclonal Antibody by Country
7.1.1 Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023)
7.1.2 Europe PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023)
7.2 Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Type
7.3 Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody by Country
8.1.1 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023)
8.1.2 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023)
8.2 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Type
8.3 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PD-1 and PD-L1 Monoclonal Antibody
10.3 Manufacturing Process Analysis of PD-1 and PD-L1 Monoclonal Antibody
10.4 Industry Chain Structure of PD-1 and PD-L1 Monoclonal Antibody
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PD-1 and PD-L1 Monoclonal Antibody Distributors
11.3 PD-1 and PD-L1 Monoclonal Antibody Customer
12 WORLD FORECAST REVIEW FOR PD-1 AND PD-L1 MONOCLONAL ANTIBODY BY GEOGRAPHIC REGION
12.1 Global PD-1 and PD-L1 Monoclonal Antibody Market Size Forecast by Region
12.1.1 Global PD-1 and PD-L1 Monoclonal Antibody Forecast by Region (2024-2029)
12.1.2 Global PD-1 and PD-L1 Monoclonal Antibody Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global PD-1 and PD-L1 Monoclonal Antibody Forecast by Type
12.7 Global PD-1 and PD-L1 Monoclonal Antibody Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Merk
13.1.1 Merk Company Information
13.1.2 Merk PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.1.3 Merk PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Merk Main Business Overview
13.1.5 Merk Latest Developments
13.2 Bristol-Myers Squibb Company
13.2.1 Bristol-Myers Squibb Company Company Information
13.2.2 Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.2.3 Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Bristol-Myers Squibb Company Main Business Overview
13.2.5 Bristol-Myers Squibb Company Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.3.3 Roche PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.4.3 Pfizer PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 AstraZeneca
13.5.1 AstraZeneca Company Information
13.5.2 AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.5.3 AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 AstraZeneca Main Business Overview
13.5.5 AstraZeneca Latest Developments
13.6 Junshi Biosciences
13.6.1 Junshi Biosciences Company Information
13.6.2 Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.6.3 Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Junshi Biosciences Main Business Overview
13.6.5 Junshi Biosciences Latest Developments
13.7 Innovent
13.7.1 Innovent Company Information
13.7.2 Innovent PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.7.3 Innovent PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Innovent Main Business Overview
13.7.5 Innovent Latest Developments
13.8 Hengrui
13.8.1 Hengrui Company Information
13.8.2 Hengrui PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.8.3 Hengrui PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Hengrui Main Business Overview
13.8.5 Hengrui Latest Developments
13.9 BeiGene
13.9.1 BeiGene Company Information
13.9.2 BeiGene PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.9.3 BeiGene PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 BeiGene Main Business Overview
13.9.5 BeiGene Latest Developments
13.10 Alphamab Oncology
13.10.1 Alphamab Oncology Company Information
13.10.2 Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.10.3 Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Alphamab Oncology Main Business Overview
13.10.5 Alphamab Oncology Latest Developments
13.11 Cstone
13.11.1 Cstone Company Information
13.11.2 Cstone PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.11.3 Cstone PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Cstone Main Business Overview
13.11.5 Cstone Latest Developments
13.12 Akeso
13.12.1 Akeso Company Information
13.12.2 Akeso PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
13.12.3 Akeso PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Akeso Main Business Overview
13.12.5 Akeso Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. PD-1 and PD-L1 Monoclonal Antibody Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. PD-1 and PD-L1 Monoclonal Antibody Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of PD-1
Table 4. Major Players of PD-L1
Table 5. Global PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2018-2023) & (Units)
Table 6. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2018-2023)
Table 7. Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Type (2018-2023) & ($ million)
Table 8. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Type (2018-2023)
Table 9. Global PD-1 and PD-L1 Monoclonal Antibody Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2018-2023) & (Units)
Table 11. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2018-2023)
Table 12. Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Application (2018-2023)
Table 13. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Application (2018-2023)
Table 14. Global PD-1 and PD-L1 Monoclonal Antibody Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global PD-1 and PD-L1 Monoclonal Antibody Sales by Company (2018-2023) & (Units)
Table 16. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Company (2018-2023)
Table 17. Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Company (2018-2023) ($ Millions)
Table 18. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Company (2018-2023)
Table 19. Global PD-1 and PD-L1 Monoclonal Antibody Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers PD-1 and PD-L1 Monoclonal Antibody Producing Area Distribution and Sales Area
Table 21. Players PD-1 and PD-L1 Monoclonal Antibody Products Offered
Table 22. PD-1 and PD-L1 Monoclonal Antibody Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global PD-1 and PD-L1 Monoclonal Antibody Sales by Geographic Region (2018-2023) & (Units)
Table 26. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share Geographic Region (2018-2023)
Table 27. Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global PD-1 and PD-L1 Monoclonal Antibody Sales by Country/Region (2018-2023) & (Units)
Table 30. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country/Region (2018-2023)
Table 31. Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023) & (Units)
Table 34. Americas PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country (2018-2023)
Table 35. Americas PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country (2018-2023)
Table 37. Americas PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2018-2023) & (Units)
Table 38. Americas PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2018-2023) & (Units)
Table 39. APAC PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2018-2023) & (Units)
Table 40. APAC PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Region (2018-2023)
Table 41. APAC PD-1 and PD-L1 Monoclonal Antibody Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Region (2018-2023)
Table 43. APAC PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2018-2023) & (Units)
Table 44. APAC PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2018-2023) & (Units)
Table 45. Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023) & (Units)
Table 46. Europe PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country (2018-2023)
Table 47. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country (2018-2023)
Table 49. Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2018-2023) & (Units)
Table 50. Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2018-2023) & (Units)
Table 51. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023) & (Units)
Table 52. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2018-2023) & (Units)
Table 56. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2018-2023) & (Units)
Table 57. Key Market Drivers & Growth Opportunities of PD-1 and PD-L1 Monoclonal Antibody
Table 58. Key Market Challenges & Risks of PD-1 and PD-L1 Monoclonal Antibody
Table 59. Key Industry Trends of PD-1 and PD-L1 Monoclonal Antibody
Table 60. PD-1 and PD-L1 Monoclonal Antibody Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. PD-1 and PD-L1 Monoclonal Antibody Distributors List
Table 63. PD-1 and PD-L1 Monoclonal Antibody Customer List
Table 64. Global PD-1 and PD-L1 Monoclonal Antibody Sales Forecast by Region (2024-2029) & (Units)
Table 65. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas PD-1 and PD-L1 Monoclonal Antibody Sales Forecast by Country (2024-2029) & (Units)
Table 67. Americas PD-1 and PD-L1 Monoclonal Antibody Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC PD-1 and PD-L1 Monoclonal Antibody Sales Forecast by Region (2024-2029) & (Units)
Table 69. APAC PD-1 and PD-L1 Monoclonal Antibody Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe PD-1 and PD-L1 Monoclonal Antibody Sales Forecast by Country (2024-2029) & (Units)
Table 71. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales Forecast by Country (2024-2029) & (Units)
Table 73. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global PD-1 and PD-L1 Monoclonal Antibody Sales Forecast by Type (2024-2029) & (Units)
Table 75. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global PD-1 and PD-L1 Monoclonal Antibody Sales Forecast by Application (2024-2029) & (Units)
Table 77. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Merk Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 79. Merk PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 80. Merk PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Merk Main Business
Table 82. Merk Latest Developments
Table 83. Bristol-Myers Squibb Company Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 84. Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 85. Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Bristol-Myers Squibb Company Main Business
Table 87. Bristol-Myers Squibb Company Latest Developments
Table 88. Roche Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 89. Roche PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 90. Roche PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Roche Main Business
Table 92. Roche Latest Developments
Table 93. Pfizer Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 95. Pfizer PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Pfizer Main Business
Table 97. Pfizer Latest Developments
Table 98. AstraZeneca Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 99. AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 100. AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. AstraZeneca Main Business
Table 102. AstraZeneca Latest Developments
Table 103. Junshi Biosciences Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 104. Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 105. Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Junshi Biosciences Main Business
Table 107. Junshi Biosciences Latest Developments
Table 108. Innovent Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 109. Innovent PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 110. Innovent PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Innovent Main Business
Table 112. Innovent Latest Developments
Table 113. Hengrui Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 114. Hengrui PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 115. Hengrui PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Hengrui Main Business
Table 117. Hengrui Latest Developments
Table 118. BeiGene Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 119. BeiGene PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 120. BeiGene PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. BeiGene Main Business
Table 122. BeiGene Latest Developments
Table 123. Alphamab Oncology Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 124. Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 125. Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Alphamab Oncology Main Business
Table 127. Alphamab Oncology Latest Developments
Table 128. Cstone Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 129. Cstone PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 130. Cstone PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 131. Cstone Main Business
Table 132. Cstone Latest Developments
Table 133. Akeso Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 134. Akeso PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 135. Akeso PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 136. Akeso Main Business
Table 137. Akeso Latest Developments
Table 1. PD-1 and PD-L1 Monoclonal Antibody Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. PD-1 and PD-L1 Monoclonal Antibody Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of PD-1
Table 4. Major Players of PD-L1
Table 5. Global PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2018-2023) & (Units)
Table 6. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2018-2023)
Table 7. Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Type (2018-2023) & ($ million)
Table 8. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Type (2018-2023)
Table 9. Global PD-1 and PD-L1 Monoclonal Antibody Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2018-2023) & (Units)
Table 11. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2018-2023)
Table 12. Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Application (2018-2023)
Table 13. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Application (2018-2023)
Table 14. Global PD-1 and PD-L1 Monoclonal Antibody Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global PD-1 and PD-L1 Monoclonal Antibody Sales by Company (2018-2023) & (Units)
Table 16. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Company (2018-2023)
Table 17. Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Company (2018-2023) ($ Millions)
Table 18. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Company (2018-2023)
Table 19. Global PD-1 and PD-L1 Monoclonal Antibody Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers PD-1 and PD-L1 Monoclonal Antibody Producing Area Distribution and Sales Area
Table 21. Players PD-1 and PD-L1 Monoclonal Antibody Products Offered
Table 22. PD-1 and PD-L1 Monoclonal Antibody Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global PD-1 and PD-L1 Monoclonal Antibody Sales by Geographic Region (2018-2023) & (Units)
Table 26. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share Geographic Region (2018-2023)
Table 27. Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global PD-1 and PD-L1 Monoclonal Antibody Sales by Country/Region (2018-2023) & (Units)
Table 30. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country/Region (2018-2023)
Table 31. Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023) & (Units)
Table 34. Americas PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country (2018-2023)
Table 35. Americas PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country (2018-2023)
Table 37. Americas PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2018-2023) & (Units)
Table 38. Americas PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2018-2023) & (Units)
Table 39. APAC PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2018-2023) & (Units)
Table 40. APAC PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Region (2018-2023)
Table 41. APAC PD-1 and PD-L1 Monoclonal Antibody Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Region (2018-2023)
Table 43. APAC PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2018-2023) & (Units)
Table 44. APAC PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2018-2023) & (Units)
Table 45. Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023) & (Units)
Table 46. Europe PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country (2018-2023)
Table 47. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country (2018-2023)
Table 49. Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2018-2023) & (Units)
Table 50. Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2018-2023) & (Units)
Table 51. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023) & (Units)
Table 52. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2018-2023) & (Units)
Table 56. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2018-2023) & (Units)
Table 57. Key Market Drivers & Growth Opportunities of PD-1 and PD-L1 Monoclonal Antibody
Table 58. Key Market Challenges & Risks of PD-1 and PD-L1 Monoclonal Antibody
Table 59. Key Industry Trends of PD-1 and PD-L1 Monoclonal Antibody
Table 60. PD-1 and PD-L1 Monoclonal Antibody Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. PD-1 and PD-L1 Monoclonal Antibody Distributors List
Table 63. PD-1 and PD-L1 Monoclonal Antibody Customer List
Table 64. Global PD-1 and PD-L1 Monoclonal Antibody Sales Forecast by Region (2024-2029) & (Units)
Table 65. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas PD-1 and PD-L1 Monoclonal Antibody Sales Forecast by Country (2024-2029) & (Units)
Table 67. Americas PD-1 and PD-L1 Monoclonal Antibody Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC PD-1 and PD-L1 Monoclonal Antibody Sales Forecast by Region (2024-2029) & (Units)
Table 69. APAC PD-1 and PD-L1 Monoclonal Antibody Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe PD-1 and PD-L1 Monoclonal Antibody Sales Forecast by Country (2024-2029) & (Units)
Table 71. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales Forecast by Country (2024-2029) & (Units)
Table 73. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global PD-1 and PD-L1 Monoclonal Antibody Sales Forecast by Type (2024-2029) & (Units)
Table 75. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global PD-1 and PD-L1 Monoclonal Antibody Sales Forecast by Application (2024-2029) & (Units)
Table 77. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Merk Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 79. Merk PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 80. Merk PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Merk Main Business
Table 82. Merk Latest Developments
Table 83. Bristol-Myers Squibb Company Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 84. Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 85. Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Bristol-Myers Squibb Company Main Business
Table 87. Bristol-Myers Squibb Company Latest Developments
Table 88. Roche Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 89. Roche PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 90. Roche PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Roche Main Business
Table 92. Roche Latest Developments
Table 93. Pfizer Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 95. Pfizer PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Pfizer Main Business
Table 97. Pfizer Latest Developments
Table 98. AstraZeneca Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 99. AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 100. AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. AstraZeneca Main Business
Table 102. AstraZeneca Latest Developments
Table 103. Junshi Biosciences Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 104. Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 105. Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Junshi Biosciences Main Business
Table 107. Junshi Biosciences Latest Developments
Table 108. Innovent Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 109. Innovent PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 110. Innovent PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Innovent Main Business
Table 112. Innovent Latest Developments
Table 113. Hengrui Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 114. Hengrui PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 115. Hengrui PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Hengrui Main Business
Table 117. Hengrui Latest Developments
Table 118. BeiGene Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 119. BeiGene PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 120. BeiGene PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. BeiGene Main Business
Table 122. BeiGene Latest Developments
Table 123. Alphamab Oncology Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 124. Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 125. Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Alphamab Oncology Main Business
Table 127. Alphamab Oncology Latest Developments
Table 128. Cstone Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 129. Cstone PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 130. Cstone PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 131. Cstone Main Business
Table 132. Cstone Latest Developments
Table 133. Akeso Basic Information, PD-1 and PD-L1 Monoclonal Antibody Manufacturing Base, Sales Area and Its Competitors
Table 134. Akeso PD-1 and PD-L1 Monoclonal Antibody Product Portfolios and Specifications
Table 135. Akeso PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 136. Akeso Main Business
Table 137. Akeso Latest Developments
LIST OF FIGURES
Figure 1. Picture of PD-1 and PD-L1 Monoclonal Antibody
Figure 2. PD-1 and PD-L1 Monoclonal Antibody Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PD-1 and PD-L1 Monoclonal Antibody Sales Growth Rate 2018-2029 (Units)
Figure 7. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of PD-1
Figure 10. Product Picture of PD-L1
Figure 11. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type in 2022
Figure 12. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Type (2018-2023)
Figure 13. PD-1 and PD-L1 Monoclonal Antibody Consumed in Lung Cancer
Figure 14. Global PD-1 and PD-L1 Monoclonal Antibody Market: Lung Cancer (2018-2023) & (Units)
Figure 15. PD-1 and PD-L1 Monoclonal Antibody Consumed in Liver Cancer
Figure 16. Global PD-1 and PD-L1 Monoclonal Antibody Market: Liver Cancer (2018-2023) & (Units)
Figure 17. PD-1 and PD-L1 Monoclonal Antibody Consumed in Esophageal Cancer
Figure 18. Global PD-1 and PD-L1 Monoclonal Antibody Market: Esophageal Cancer (2018-2023) & (Units)
Figure 19. PD-1 and PD-L1 Monoclonal Antibody Consumed in Gastric Cancer
Figure 20. Global PD-1 and PD-L1 Monoclonal Antibody Market: Gastric Cancer (2018-2023) & (Units)
Figure 21. PD-1 and PD-L1 Monoclonal Antibody Consumed in Nasopharyngeal Carcinoma
Figure 22. Global PD-1 and PD-L1 Monoclonal Antibody Market: Nasopharyngeal Carcinoma (2018-2023) & (Units)
Figure 23. PD-1 and PD-L1 Monoclonal Antibody Consumed in Head and Neck Cancer
Figure 24. Global PD-1 and PD-L1 Monoclonal Antibody Market: Head and Neck Cancer (2018-2023) & (Units)
Figure 25. PD-1 and PD-L1 Monoclonal Antibody Consumed in Other
Figure 26. Global PD-1 and PD-L1 Monoclonal Antibody Market: Other (2018-2023) & (Units)
Figure 27. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2022)
Figure 28. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Application in 2022
Figure 29. PD-1 and PD-L1 Monoclonal Antibody Sales Market by Company in 2022 (Units)
Figure 30. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Company in 2022
Figure 31. PD-1 and PD-L1 Monoclonal Antibody Revenue Market by Company in 2022 ($ Million)
Figure 32. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Company in 2022
Figure 33. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Geographic Region (2018-2023)
Figure 34. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Geographic Region in 2022
Figure 35. Americas PD-1 and PD-L1 Monoclonal Antibody Sales 2018-2023 (Units)
Figure 36. Americas PD-1 and PD-L1 Monoclonal Antibody Revenue 2018-2023 ($ Millions)
Figure 37. APAC PD-1 and PD-L1 Monoclonal Antibody Sales 2018-2023 (Units)
Figure 38. APAC PD-1 and PD-L1 Monoclonal Antibody Revenue 2018-2023 ($ Millions)
Figure 39. Europe PD-1 and PD-L1 Monoclonal Antibody Sales 2018-2023 (Units)
Figure 40. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue 2018-2023 ($ Millions)
Figure 41. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales 2018-2023 (Units)
Figure 42. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue 2018-2023 ($ Millions)
Figure 43. Americas PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country in 2022
Figure 44. Americas PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country in 2022
Figure 45. Americas PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2018-2023)
Figure 46. Americas PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2018-2023)
Figure 47. United States PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 48. Canada PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 49. Mexico PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 50. Brazil PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 51. APAC PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Region in 2022
Figure 52. APAC PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Regions in 2022
Figure 53. APAC PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2018-2023)
Figure 54. APAC PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2018-2023)
Figure 55. China PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 56. Japan PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 57. South Korea PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 58. Southeast Asia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 59. India PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 60. Australia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 61. China Taiwan PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 62. Europe PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country in 2022
Figure 63. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country in 2022
Figure 64. Europe PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2018-2023)
Figure 65. Europe PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2018-2023)
Figure 66. Germany PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 67. France PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 68. UK PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 69. Italy PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 70. Russia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 71. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country in 2022
Figure 72. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country in 2022
Figure 73. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2018-2023)
Figure 74. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2018-2023)
Figure 75. Egypt PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 76. South Africa PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 77. Israel PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 78. Turkey PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 79. GCC Country PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 80. Manufacturing Cost Structure Analysis of PD-1 and PD-L1 Monoclonal Antibody in 2022
Figure 81. Manufacturing Process Analysis of PD-1 and PD-L1 Monoclonal Antibody
Figure 82. Industry Chain Structure of PD-1 and PD-L1 Monoclonal Antibody
Figure 83. Channels of Distribution
Figure 84. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Forecast by Region (2024-2029)
Figure 85. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share Forecast by Region (2024-2029)
Figure 86. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share Forecast by Type (2024-2029)
Figure 87. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share Forecast by Type (2024-2029)
Figure 88. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share Forecast by Application (2024-2029)
Figure 89. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of PD-1 and PD-L1 Monoclonal Antibody
Figure 2. PD-1 and PD-L1 Monoclonal Antibody Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PD-1 and PD-L1 Monoclonal Antibody Sales Growth Rate 2018-2029 (Units)
Figure 7. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of PD-1
Figure 10. Product Picture of PD-L1
Figure 11. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type in 2022
Figure 12. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Type (2018-2023)
Figure 13. PD-1 and PD-L1 Monoclonal Antibody Consumed in Lung Cancer
Figure 14. Global PD-1 and PD-L1 Monoclonal Antibody Market: Lung Cancer (2018-2023) & (Units)
Figure 15. PD-1 and PD-L1 Monoclonal Antibody Consumed in Liver Cancer
Figure 16. Global PD-1 and PD-L1 Monoclonal Antibody Market: Liver Cancer (2018-2023) & (Units)
Figure 17. PD-1 and PD-L1 Monoclonal Antibody Consumed in Esophageal Cancer
Figure 18. Global PD-1 and PD-L1 Monoclonal Antibody Market: Esophageal Cancer (2018-2023) & (Units)
Figure 19. PD-1 and PD-L1 Monoclonal Antibody Consumed in Gastric Cancer
Figure 20. Global PD-1 and PD-L1 Monoclonal Antibody Market: Gastric Cancer (2018-2023) & (Units)
Figure 21. PD-1 and PD-L1 Monoclonal Antibody Consumed in Nasopharyngeal Carcinoma
Figure 22. Global PD-1 and PD-L1 Monoclonal Antibody Market: Nasopharyngeal Carcinoma (2018-2023) & (Units)
Figure 23. PD-1 and PD-L1 Monoclonal Antibody Consumed in Head and Neck Cancer
Figure 24. Global PD-1 and PD-L1 Monoclonal Antibody Market: Head and Neck Cancer (2018-2023) & (Units)
Figure 25. PD-1 and PD-L1 Monoclonal Antibody Consumed in Other
Figure 26. Global PD-1 and PD-L1 Monoclonal Antibody Market: Other (2018-2023) & (Units)
Figure 27. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2022)
Figure 28. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Application in 2022
Figure 29. PD-1 and PD-L1 Monoclonal Antibody Sales Market by Company in 2022 (Units)
Figure 30. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Company in 2022
Figure 31. PD-1 and PD-L1 Monoclonal Antibody Revenue Market by Company in 2022 ($ Million)
Figure 32. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Company in 2022
Figure 33. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Geographic Region (2018-2023)
Figure 34. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Geographic Region in 2022
Figure 35. Americas PD-1 and PD-L1 Monoclonal Antibody Sales 2018-2023 (Units)
Figure 36. Americas PD-1 and PD-L1 Monoclonal Antibody Revenue 2018-2023 ($ Millions)
Figure 37. APAC PD-1 and PD-L1 Monoclonal Antibody Sales 2018-2023 (Units)
Figure 38. APAC PD-1 and PD-L1 Monoclonal Antibody Revenue 2018-2023 ($ Millions)
Figure 39. Europe PD-1 and PD-L1 Monoclonal Antibody Sales 2018-2023 (Units)
Figure 40. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue 2018-2023 ($ Millions)
Figure 41. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales 2018-2023 (Units)
Figure 42. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue 2018-2023 ($ Millions)
Figure 43. Americas PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country in 2022
Figure 44. Americas PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country in 2022
Figure 45. Americas PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2018-2023)
Figure 46. Americas PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2018-2023)
Figure 47. United States PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 48. Canada PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 49. Mexico PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 50. Brazil PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 51. APAC PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Region in 2022
Figure 52. APAC PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Regions in 2022
Figure 53. APAC PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2018-2023)
Figure 54. APAC PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2018-2023)
Figure 55. China PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 56. Japan PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 57. South Korea PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 58. Southeast Asia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 59. India PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 60. Australia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 61. China Taiwan PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 62. Europe PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country in 2022
Figure 63. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country in 2022
Figure 64. Europe PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2018-2023)
Figure 65. Europe PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2018-2023)
Figure 66. Germany PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 67. France PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 68. UK PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 69. Italy PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 70. Russia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 71. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country in 2022
Figure 72. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country in 2022
Figure 73. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2018-2023)
Figure 74. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2018-2023)
Figure 75. Egypt PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 76. South Africa PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 77. Israel PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 78. Turkey PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 79. GCC Country PD-1 and PD-L1 Monoclonal Antibody Revenue Growth 2018-2023 ($ Millions)
Figure 80. Manufacturing Cost Structure Analysis of PD-1 and PD-L1 Monoclonal Antibody in 2022
Figure 81. Manufacturing Process Analysis of PD-1 and PD-L1 Monoclonal Antibody
Figure 82. Industry Chain Structure of PD-1 and PD-L1 Monoclonal Antibody
Figure 83. Channels of Distribution
Figure 84. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Forecast by Region (2024-2029)
Figure 85. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share Forecast by Region (2024-2029)
Figure 86. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share Forecast by Type (2024-2029)
Figure 87. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share Forecast by Type (2024-2029)
Figure 88. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share Forecast by Application (2024-2029)
Figure 89. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share Forecast by Application (2024-2029)
